ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · IEX Real-Time Price · USD
4.910
-0.330 (-6.30%)
At close: Apr 18, 2024, 4:00 PM
4.940
+0.030 (0.61%)
After-hours: Apr 18, 2024, 7:59 PM EDT
ImmunityBio Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for ImmunityBio stock has a target of 5.00, which predicts an increase of 1.83% from the current stock price of 4.91.
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for ImmunityBio is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|
| Strong Buy | 1 | 1 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Hold Maintains $4 → $5 | Hold | Maintains | $4 → $5 | +1.83% | Mar 25, 2024 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $10 → $4 | Buy → Hold | Downgrades | $10 → $4 | -18.53% | May 12, 2023 |
| Jefferies | Jefferies | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +62.93% | Aug 3, 2022 |
Financial Forecast
Revenue This Year
9.87M
from 622.00K
Increased by 1,487.46%
Revenue Next Year
86.37M
from 9.87M
Increased by 774.76%
EPS This Year
-0.69
from -1.15
EPS Next Year
-0.46
from -0.69
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 10.2M | 88.9M | 207.5M |
| Avg | 9.9M | 86.4M | 201.5M |
| Low | 9.5M | 83.0M | 193.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 1,534.1% | 800.5% | 140.2% |
| Avg | 1,487.5% | 774.8% | 133.3% |
| Low | 1,425.1% | 740.4% | 124.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.71 | -0.47 | -0.36 |
| Avg | -0.69 | -0.46 | -0.35 |
| Low | -0.67 | -0.44 | -0.33 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.